Quintiles completes 400th trial using electronic data capture
pharmafile | April 7, 2009 | News story | Research and Development |Â Â CRO, QuintilesÂ
Quintiles has completed its 400th clinical trial using Electronic Data Capture (EDC).
In addition to starting its 400th EDC trial, Quintiles has locked databases – the final step in data capture – on more than 270 EDC trials since 2000.
To date, Quintiles has enrolled more than 400,000 patients at about 30,000 sites around the world using the technology.
The study in question is a phase II trial for AstraZeneca's AZD7325 – a GABA receptor sub-type partial agonist being developed for the treatment of anxiety.
"We are delighted that AstraZeneca has chosen Quintiles to help in the development of its innovative anti-anxiety medicine," said Paula Brown Stafford, executive vice president of Integrated Clinical Services at Quintiles. "As the industry continues to adopt EDC and other time-saving technologies and processes, more patients will benefit sooner from new, breakthrough therapies."
Alex O'Toole, global head of EDC for Quintiles, said: "Quintiles' ability to scale up the use of EDC while maintaining great performance for our customers and our clinical investigators is unparalleled in the CRO marketplace.
"We know this from regular surveys of our users that allow us to track their experience as we increase the number of EDC trials. Our surveys also help us to confirm the right system choice. We find that the majority of our investigators prefer the systems we offer and that the functionality helps them do their jobs more effectively."
The phase II trial is a study of AZD 7325 for generalised anxiety disorder. Quintiles will use EDC to improve quality and shorten the time needed for evaluation of data at the conclusion of the study.
Brad Bower, one of AstraZeneca's clinical leaders within the Neuroscience area, said: "We selected Quintiles to support delivery of this study because of their extensive clinical research expertise, experience and global reach.
"We ourselves look to leverage the benefits of technology in the delivery of our studies including web-based data capture, so the fact that they have harnessed EDC for this trial helps to enhance the delivery and efficiency of the programme."
Related Content
Crown Bioscience opens new US model development centre
Crown Bioscience, a US global contract research organisation (CRO) that is part of JSR Life …
From molecule to market and beyond: Uniphar announces extended global commercialization platform
22 October 2024 – Dublin, Ireland – Healthcare services business, Uniphar, has developed its full-service …
Quintiles to merge with IMS Health
IMS Health (NYSE: IMS) and Quintiles (NYSE: Q) have announced that a definitive merger agreement …
